CLINICAL NEWS
increased gamma-glutamyltransferase (n=7; 8.8%), dyspnea (n=4;
5.0%), and fatigue (n=4; 5.0%).
The most common hematologic abnormalities included decreased
hemoglobin (all-grade, n=74 [96.1%]; grade ≥3, n=9 [11.7%]), neutro-
penia (all-grade, n=42 [60.9%]; any-grade, n=29 [42.0%]), and throm-
bocytopenia (all-grade, n=55 [71.4%]; any-grade, n=21 [27.3%]).
“Almost everybody had some toxicity, the most common of which
were skin-related changes (n=72; 52.2%),” Dr. Kahl reported, with “ex-
cessive toxicities more likely to appear in cycles two and three.” Though
not severe, he added, “toxicities could be persistent.”
Eight patients (10%) discontinued treatment due to AEs (including
increased gamma-glutamyltransferase [n=4]; increased blood alkaline
phosphatase [n=1]; periorbital edema [n=1]; fatigue [n=1]; abdominal
pain [n=1]; and thrombocytopenia [n=1]).
Response was evaluable in 68 patients receiving loncastuximab te-
sirine ≥120 µg/kg. The ORR was 60.3 percent (n=41), with 24 patients
(35.3%) experiencing complete response (CR) and 17 (25.0%) experi-
encing partial response (PR).
“Follow-up is short and early,” Dr. Kahl noted as a limitation of
the analysis, but “the agent shows encouraging single-agent activity in
fairly unfavorable patients.” Future studies will evaluate loncastuximab
tesirine in specific NHL subtypes, Dr. Kahl concluded, adding that a
dose-expansion phase in patients with DLBCL is being planned.
The authors report financial relationships with ADC Therapeutics, the
manufacturer of loncastuximab tesirine.
REFERENCE
Kahl BS, Hamadani M, Caimi P, et al. Encouraging early results from the first-in-human clinical trial of Adct-402
(loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell
Lineage non-Hodgkin lymphoma. Abstract #187. Presented at the 2017 ASH Annual Meeting, December 9, 2017; Atlanta, GA.
ASH Central at the 2017 ASH Annual Meeting.
Save the Date!
60th ASH
Annual
Meeting and
Exposition
®
San Diego, California
December 1-4, 2018
Connect with the world of
hematology at the premier
event of the year!
www.hematology.org/annualmeeting